Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS

Journal of Biomolecular Techniques

Volumn 19, Issue 3, 2008, Pages 167-176

  Borges, Chad R ^a   Jarvis, Jason W ^a   Oran, Paul E ^a   Rogers, Stephen P ^a   Nelson, Randall W ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Electrospray ionization; Mass spectrometric immunoassay; Microheterogeneity; Vitamin D binding protein

Indexed keywords

BIOLOGICAL MARKER; VITAMIN D BINDING PROTEIN;

ALLELE; ARTICLE; BIOTECHNOLOGY; BLOOD; BLOOD ANALYSIS; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; GENETICS; GENOTYPE; GLYCOSYLATION; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; METHODOLOGY; POPULATION GENETICS; PROTEOMICS;

ALLELES; BIOLOGICAL MARKERS; BIOTECHNOLOGY; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; GENETICS, POPULATION; GENOTYPE; GLYCOSYLATION; HUMANS; IMMUNOASSAY; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VITAMIN D-BINDING PROTEIN;

EID: 63449108335     PISSN: 15240215     EISSN: 19434731     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Mann M, Wilm M. Electrospray mass spectrometry for protein characterization. Trends Biochem Sci 1995;20:219-224.
2. Siuzdak G. The emergence of mass spectrometry in biochemical research. Proc Natl Acad Sci USA 1994;19:11290.
3. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW. Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics 2004;4:1825-1829.
4. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW. Selected expression profiling of full-length proteins and their variants in human plasma. Clin Proteomics 2004;1:7-16.
5. Kiernan UA, Tubbs, KA, Gruber K, et al. High-throughput protein characterization using mass spectrometric immunoassay. Anal Biochem 2002;301:49-56.
6. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 2003;537:166-170.
7. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 2005;102:10852-10857.
8. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW. Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics 2007;6:1183-1187.
9. Nedelkov D, Tubbs KA, Niederkofler EE, Kiernan UA, Nelson RW. High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. Anal Chem 2004;76:1733-1737.
10. Niederkofler EE, Tubbs KA, Gruber K, et al. Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 2001;73:3294-3299.
11. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 2003;44:630-639.
12. Wu J, Watson JT. A novel methodology for assignment of disulfide bond pairings in proteins. Protein Sci 1997;6:391-398.
13. Qi J, Wu J, Somkuti GA, Watson JT. Determination of the disulfide structure of sillucin, a highly knotted, cysteine-rich peptide, by cyanylation/cleavage mass mapping. Biochemistry 2001;40:4531-4538.
14. Qi J, Wu W, Borges CR, Hang D, Rupp M, Torng E, Watson JT. Automated data interpretation based on the concept of "negative signature mass" for mass-mapping disulfide structures of cystinyl proteins. J Am Soc Mass Spectrom 2003;14:1032-1038.
15. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001;2001:PL1.
16. Borges CR, Qi J, Wu W, Torng E, Hinck AP, Watson, JT. Algorithm-assisted elucidation of disulfide structure: application of the negative signature mass algorithm to mass-mapping the disulfide structure of the 12-cysteine transforming growth factor beta type II receptor extracellular domain. Anal Biochem 2004;329:91-103.
17. Kiernan UA, Addobbati R, Nedelkov D, Nelson RW. Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res 2006;5:1682-1687.
18. Nelson RW, Krone JR, Bieber AL, Williams P. Mass spectrometric immunoassay. Anal Chem 1995;67:1153-1158.
19. Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA. Quantitative mass spectrometric immunoassay of insulin like growth factor 1. J Proteome Res 2004;3:851-855.
20. Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW. Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Anal Chem 2006;78:3271-3276.
21. Tubbs KA, Nedelkov D, Nelson RW. Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. Anal Biochem 2001;289:26-35.
22. Kiernan UA, Nedelkov D, Nelson RW. Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res 2006;5:2928-2934.
23. Hermanson GT, Krishna Mallia A, Smith PK. Immobilized Affinity Ligand Techniques. San Diego, CA, Academic Press, 1992, 64-69.
24. Hirschfeld J, Jonsson B, Rasmuson M. Inheritance of a new group-specific system demonstrated in normal human sera by means of an immuno-electrophoretic technique. Nature 1960;185:931-932.
25. Cleve H, Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox sang 1988;54:215-225.
26. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clinica Chim Acta 2006;372:33-42.
27. Viau M, Constans J, Debray H, Montreuil J. Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein. Biochem Biophys Res Commun 1983;117:324-331.
28. Yamamoto N. Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. Mol Immunol 1996;33:1157-1164.
29. Yamamoto N, Homma S. Vitamin D3 binding protein (groupspecific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholinetreated lymphocytes. Proc Natl Acad Sci USA 1991;88:8539-8543.
30. Borges CR, Jarvis JW, Oran PE, Nelson RW. Population studies of vitamin D binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J Proteome Res 2008; Epub ahead of print.
31. Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of betagalactosidase of B cells and sialidase of T cells. J Immunol 1993;151:2794-2802.
32. Nagasawa H, Uto Y, Sasaki H, et al. Gc protein (vitamin D-binding protein): Gc genotyping GcMAF precursor activity. Anticancer Res 2005;25:3689-3695.
33. Ohkura, K, Nagasawa H, Uto Y, Okamura N, Murakami A, Hori H. The role of Gc protein oligosaccharide structure as a risk factor for COPD. Anticancer Res 2006;26:4073-4078.
34. Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS. Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 2005;28:645-652.
35. Kirk RL, Serjeanston SW, Zimmet P. Genes and diabetes in the Pacific. In Mimura G, Baba S, Goto Y, Kobberling J (eds): Clinicogenetic Genesis of Diabetes Mellitus. Amsterdam: Excepta Medica, 1982:34-41.
36. Hirai M, Suzuki S, Hinokio Y, et al. Group specific component protein genotype is associated with NIDDM in Japan. Diabetologia 1998;41:742-743.
37. Ye WZ, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. Variations in the vitamin D-binding protein (Gc locus) and risk of type 2 diabetes mellitus in French Caucasians. Metabolism 2001;50:366-369.
38. Klupa T, Malecki M, Hanna L, et al. Amino acid variants of the vitamin D-binding protein and risk of diabetes in white Americans of European origin. Eur J Endocrinol 1999;141:490-493.
39. Malecki MT, Klupa T, Wanic K, Cyganek K, Frey J, Sieradzki J. Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clinical Practice 2002;57:99-104.
40. Christiansen M, Jorgensen CS, Laursen I, Hirschberg D, Hojrup P, Houen G. Protein chemical characterization of Gc globulin (vitamin D-binding protein) isoforms; Gc-1f, Gc-1s and Gc-2. Biochim Biophys Acta 2007;1774:481-492.
41. Yamamoto N, Homma S, Millman, I. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 1991;147:273-280.